The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review
AL Brand, PE Lawler, JG Bollinger, Y Li… - Alzheimer's research & …, 2022 - Springer
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies
JC Polanco, C Li, LG Bodea… - Nature Reviews …, 2018 - nature.com
Most neurodegenerative diseases are proteinopathies, which are characterized by the
aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to …
aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
70-year legacy of the Framingham Heart Study
Abstract The Framingham Heart Study (FHS) was established in 1948 to improve
understanding of the epidemiology of coronary heart disease (CHD) in the USA. In 1961 …
understanding of the epidemiology of coronary heart disease (CHD) in the USA. In 1961 …
Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
The last decade has seen a substantial increase in research focused on the identification of
blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based …
blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based …
Blood-based biomarkers for Alzheimer's disease diagnosis and progression: an overview
A Varesi, A Carrara, VG Pires, V Floris, E Pierella… - Cells, 2022 - mdpi.com
Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Objective To explore whether the plasma total β-amyloid (Aβ) Aβ42/Aβ40 ratio is a reliable
predictor of the amyloid-PET status by exploring the association between these 2 variables …
predictor of the amyloid-PET status by exploring the association between these 2 variables …
Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE …
C Sheng, K Yang, B He, W Du, Y Cai, Y Han - Alzheimer's research & …, 2022 - Springer
Background Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain
amyloidosis. Gut microbial dysbiosis in Alzheimer's disease (AD) is increasingly being …
amyloidosis. Gut microbial dysbiosis in Alzheimer's disease (AD) is increasingly being …
[HTML][HTML] Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
Introduction Plasma amyloid β (Aβ) peptides have been previously studied as candidate
biomarkers to increase recruitment efficiency in secondary prevention clinical trials for …
biomarkers to increase recruitment efficiency in secondary prevention clinical trials for …
Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease
M Ghahremani, M Wang, HY Chen, H Zetterberg… - Neurology, 2023 - AAN Enterprises
Background and Objectives Plasma phosphorylated tau at threonine 181 (p-tau181), a well-
validated marker of Alzheimer disease (AD) pathologic change, could be a more efficient …
validated marker of Alzheimer disease (AD) pathologic change, could be a more efficient …